At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Durvalumab, Hypofractionated Radiation Therapy, and 2 other interventions for Recurrent Small Cell Lung Carcinoma. Completed, enrolled 18 participants across 2 sites.
Detailed Summary
This randomized clinical trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may limit the ability of tumor cells to grow and spread by enhancing immune function. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tremelimumab and durvalumab together with radiation therapy may lead to improved clinical benefit.
Study Details
Timeline
Interventions
Given IV
Undergo hypofractionated radiation therapy
Undergo SBRT
Given IV